5月19日 - ** 制药商REGENON Pharmaceuticals REGN.O股价盘前上涨2%至606美元
** REGN称 (link)，已同意以2.56亿美元收购破产的 基因检测公司23andMe Holding。
** 该协议不包括收购 23andMe 的远程医疗服务 Lemonaid Health
** 23andMe的破产程序引起了立法者的关注，他们警告说，数百万客户的基因数据可能会被出售给不法买家。
** Regeneron 表示，它将遵守23andMe的隐私政策和有关客户数据使用的适用法律，并已准备好向法院指定的监督员详细说明它打算如何使用这些数据。
** 截至上一交易日收盘，REGN 年度累计下跌 16.6
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.